Mirae Asset Global Investments Co. Ltd. reduced its position in shares of Humana Inc. (NYSE:HUM) by 23.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,642 shares of the insurance provider’s stock after selling 7,477 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Humana were worth $10,332,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Humana by 3.2% in the first quarter. BlackRock Inc. now owns 12,352,180 shares of the insurance provider’s stock worth $5,178,651,000 after buying an additional 385,141 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Humana by 7.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,989,308 shares of the insurance provider’s stock worth $4,098,313,000 after purchasing an additional 656,606 shares in the last quarter. Norges Bank acquired a new position in Humana during the 4th quarter worth approximately $601,429,000. Newport Trust Co boosted its holdings in shares of Humana by 1.4% in the 1st quarter. Newport Trust Co now owns 1,464,234 shares of the insurance provider’s stock valued at $613,880,000 after buying an additional 20,452 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Humana by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,343,027 shares of the insurance provider’s stock worth $550,958,000 after buying an additional 41,170 shares during the period. Institutional investors own 92.11% of the company’s stock.
Several equities research analysts recently issued reports on HUM shares. Citigroup upped their price target on Humana from $496.00 to $510.00 in a report on Thursday, April 29th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their price objective on Humana from $496.00 to $510.00 and gave the company a “buy” rating in a research report on Thursday, April 29th. Mizuho upped their target price on Humana from $462.00 to $480.00 and gave the stock a “buy” rating in a report on Thursday, April 29th. Wells Fargo & Company began coverage on shares of Humana in a research note on Monday, May 24th. They issued an “equal weight” rating and a $472.00 price target on the stock. Finally, Zacks Investment Research cut shares of Humana from a “hold” rating to a “sell” rating and set a $447.00 price target for the company. in a research report on Tuesday, March 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $475.94.
Shares of HUM opened at $435.73 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.67 and a quick ratio of 1.67. The firm has a market cap of $56.22 billion, a PE ratio of 15.50, a P/E/G ratio of 1.47 and a beta of 0.88. The stock has a 50 day simple moving average of $440.20. Humana Inc. has a 12-month low of $365.06 and a 12-month high of $475.44.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 28th. The insurance provider reported $7.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.21 by $0.46. The business had revenue of $20.67 billion during the quarter, compared to analysts’ expectations of $20.42 billion. Humana had a return on equity of 19.08% and a net margin of 4.72%. Humana’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.40 EPS. On average, equities research analysts forecast that Humana Inc. will post 21.64 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 30th. Shareholders of record on Wednesday, June 30th will be given a $0.70 dividend. The ex-dividend date is Tuesday, June 29th. This represents a $2.80 annualized dividend and a yield of 0.64%. Humana’s dividend payout ratio is currently 14.93%.
In other news, insider Timothy Alan Wheatley sold 8,508 shares of the firm’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $450.59, for a total value of $3,833,619.72. Following the transaction, the insider now directly owns 11,494 shares in the company, valued at approximately $5,179,081.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Christopher H. Hunter sold 5,156 shares of the business’s stock in a transaction dated Thursday, April 29th. The shares were sold at an average price of $443.76, for a total value of $2,288,026.56. Following the completion of the transaction, the insider now owns 8,653 shares in the company, valued at $3,839,855.28. The disclosure for this sale can be found here. 0.40% of the stock is owned by corporate insiders.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Shanghai Stock Exchange Composite Index
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).